BIO-THERA SOLUTIONS LTD
BiotechBIO-THERA SOLUTIONS LTD is a biotechnology company focused on Oncology, Immunology, Ophthalmology.
BIO-THERA SOLUTIONS LTD at a Glance
- Fast trial execution (25 months median completion)
BIO-THERA SOLUTIONS LTD's Key Drugs
BIO-THERA SOLUTIONS LTD's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
BIO-THERA SOLUTIONS LTD's Recent FDA Approvals
BIO-THERA SOLUTIONS LTD secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
BIO-THERA SOLUTIONS LTD's Therapeutic Areas
BIO-THERA SOLUTIONS LTD's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
BIO-THERA SOLUTIONS LTD's Top Competitors
BIO-THERA SOLUTIONS LTD's closest competitors by therapeutic-area and drug-target overlap include BAUSCH, Pfizer, and Novartis. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
BIO-THERA SOLUTIONS LTD Pipeline Snapshot
BIO-THERA SOLUTIONS LTD has 38 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 3 Phase 2 and 27 Phase 1.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 7/9 completed
- • Speed: 25 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-12-06
- Latest
- 2025-05-22
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges